Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study

Alzheon won’t be profiting from an IPO soon.

The tiny biotech, which has been trying to fund a late-stage trial for a once-failed drug called ALZ-801 (tramiprosate), notified investors on Friday that they’re postponing the IPO they filed in search of about $70 million or $80 million, according to an alert from Renaissance Capital.